Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II

The association of the immunohistochemical expressions of cyclin DI, p16 and the retinoblastoma gene product (pRB) with the prognoses of 106 patients with non-small cell lung cancer (NSCLC) at stages I and II after a complete resection was investigated. We used antibodies recognizing nuclear and cytoplasmic cyclin DI, p16 and pRB. In 106 tumors, the positive rates of cyclin DI, p16 and pRB were 46, 54 and 48%, respectively. Cyclin DI-positive (cyclin DI+) patients had significantly poorer survival prognoses than cyclin DI-negative (cyclin DI-) patients (log-rank test, P=0.0002; Wilcoxon test, P=0.0005), whereas p16-positive (p16(+)) patients had significantly better prognoses than p16-negative (p16(-)) patients (log-rank test, P=0.0063; Wilcoxon test, P=0.0044). The survival period was over 65% for patients with cyclin D1(-)/p16(+) (n = 34) at 120 months after surgery, whereas patients with cyclin D1(+)/p16(-) patients (n = 22) had a 50% survival period at 49 months. The cumulative survival rate of cyclin D1(+)/p16(-) patients was significantly lower than that of cyclin D1(-)/p16(+) patients (log-rank test, P=0.0004; Wilcoxon test, P=0.0002). The pRB did not influence significantly the survival rate. Our results indicate that cyclin DI and p16, especially a combination of cyclin DI and p16, are very useful to predict the prognosis of patient with NSCLC after curative resection independent of pathological stages I and II. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.